Publications

Robert Redner, MD

Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE. A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma. 2018 Nov;59(11):2595-2601. doi: 10.1080/10428194.2018.1443330. PubMed PMID: 29616864; PMCID: PMC6201295.
Mazharuddin S, Chattopadhyay A, Levy MY, Redner RL. IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid. Leuk Lymphoma. 2018 Sep;59(9):2246-2249. doi: 10.1080/10428194.2017.1421761. PubMed PMID: 29350080; PMCID: PMC6162987.
Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 Oct;19(10):1225-1232. doi: 10.1016/j.jcyt.2017.07.008. PubMed PMID: 28864289.
Lontos K, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Saul M, Gooding WE, Humar A, Boyiadzis M. Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation. Clin Transplant. 2017 Sep;31(9): doi: 10.1111/ctr.13052. PubMed PMID: 28710776.
Lim MJ, Agha A, Im A, Raptis A, Hou JZ, Boyiadzis M, Sehgal AR, Redner RL, Dorritie K, Marks SS, Agha ME, Lim SH. Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia. Hematol Oncol. 2018 Apr;36(2):495-497. doi: 10.1002/hon.2456. PubMed PMID: 28664979.
Villgran V, Agha M, Raptis A, Hou JZ, Farah R, Lim SH, Redner RL, Im A, Sehgal A, Dorritie KA, Kiss JE, Normolle D, Boyiadzis M. Leukapheresis in patients newly diagnosed with acute myeloid leukemia. Transfus Apher Sci. 2016 Oct;55(2):216-220. doi: 10.1016/j.transci.2016.07.001. PubMed PMID: 27470709.
Im A, Amjad A, Agha M, Raptis A, Hou JZ, Farah R, Lim S, Sehgal A, Dorritie KA, Redner RL, McLaughlin B, Shuai Y, Duggal S, Boyiadzis M. Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse. Oncol Res. 2016;24(2):73-80. doi: 10.3727/096504016X14586627440156. PubMed PMID: 27296947.
Swaney EM, Chattopadhyay A, Abecassis I, Rush EA, Redner RL. The leukemic oncoprotein NPM1-RARA inhibits TP53 activity. Leuk Lymphoma. 2016 Aug;57(8):1933-7. doi: 10.3109/10428194.2015.1124992. PubMed PMID: 26754533; PMCID: PMC5023140.
Soni A, Djokic M, Hou JZ, Redner RL, Boyiadzis M. Outcomes of acute myeloid leukemia with t(15;17) not associated with acute promyelocytic leukemia. Leuk Lymphoma. 2015;56(11):3236-9. doi: 10.3109/10428194.2015.1036262. PubMed PMID: 25860246.
Chattopadhyay A, Abecassis I, Redner RL. NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNK. Leuk Lymphoma. 2015;56(12):3401-3406. doi: 10.3109/10428194.2015.1023799. PubMed PMID: 25791120; PMCID: PMC4743255.
Ross K, Gillespie-Twardy AL, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Duggal S, Ding F, Lin Y, Boyiadzis M. Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia. Oncol Res. 2015;22(2):85-92. doi: 10.3727/096504014X14146137738547. PubMed PMID: 25706395.
Johnson DE, Redner RL. An ATRActive future for differentiation therapy in AML. Blood Rev. 2015 Jul;29(4):263-8. doi: 10.1016/j.blre.2015.01.002. PubMed PMID: 25631637; PMCID: PMC4494875.
Chattopadhyay A, Hood BL, Conrads TP, Redner RL. Extrinsic apoptosis is impeded by direct binding of the APL fusion protein NPM-RAR to TRADD. Mol Cancer Res. 2014 Sep;12(9):1283-91. doi: 10.1158/1541-7786.MCR-14-0080. PubMed PMID: 25033841; PMCID: PMC4163521.
Dorritie KA, Redner RL, Johnson DE. STAT transcription factors in normal and cancer stem cells. Adv Biol Regul. 2014 Sep;5630-44. doi: 10.1016/j.jbior.2014.05.004. PubMed PMID: 24931719.
Pollock SL, Rush EA, Redner RL. NPM-RAR, not the RAR-NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation. Leuk Lymphoma. 2014 Jun;55(6):1383-7. doi: 10.3109/10428194.2013.830303. PubMed PMID: 23927396.

<< Investigators Search

Top